Pediatr Infect Dis J. 2013;32(3):264-265. The world of pediatric pneumonia and meningitis prevention has been the focus of massive scientific discovery, vaccine development and implementation efforts ...

Please provide your email address to receive an email when new articles are posted on . The winter holidays bring generations of families together. The season also brings a heightened risk for ...

(HealthDay)—Pneumococcal conjugate vaccine 13 (PCV13) should be administered to certain children aged 6 through 18 years who are at high risk of invasive pneumococcal disease (IPD), according to a ...

Please provide your email address to receive an email when new articles are posted on . The CDC’s Advisory Committee on Immunization Practices and the AAP have updated recommendations for use of the ...

(HealthDay)—For pediatric and adolescent oncology patients, a single-dose 13-valent pneumococcal conjugate vaccine (PCV13) is safe and immunogenic, according to a study published online July 11 in ...

PHILADELPHIA — The use of PCV13, a 13-valent pneumococcal conjugate vaccine (Prevnar13, Pfizer), in children has dramatically reduced the incidence of invasive pneumococcal disease in children and ...

Give the 13-valent pneumococcal conjugate vaccine to senior patients Give the 13-valent pneumococcal conjugate vaccine along with the 23-valent pneumococcal polysaccharide vaccine to all patients aged ...

Research presented during IDWeek 2021 showed data on V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine. Investigators from Merck presented 2 abstracts during IDWeek 2021 with data ...

Shingles For most serotypes, there is no significant difference in the protection conferred from four different pneumococcal vaccine schedules. HealthDay News — The immunogenicity of 13-valent ...

(HealthDay News) — Pneumococcal conjugate vaccine 13 (PCV13) should be administered to certain children aged 6 through 18 years who are at high risk of invasive pneumococcal disease (IPD), according ...